Mount Sinai researchers develop first mathematical model for predicting patient response to immunotherapyThe Cancer Letter PublicationsResearchers at the Icahn School of Medicine at Mount Sinai have created the first mathematical model that can predict… Continue reading
Mount Sinai researchers develop first mathematical model for predicting patient response to immunotherapyThe Cancer Letter PublicationsResearchers at the Icahn School of Medicine at Mount Sinai have created the first mathematical model that can predict… Continue reading
Lab News |
Promising gene therapy treatment for blindness
Lab News Most causes of untreatable blindness occur from the loss of millions of light sensitive photoreceptor cells that line the retina. Even after a patient’s eyesight has been lost, the remaining cells that are not light-sensitive are still intact … |
Journalism Day |
Stem cells ‘will enable us to live to 200’
The Scotsman Stem cells will enable people to live to an average of 200 years, a Nottingham-based stem cell bank has claimed. It pointed to trials in the United States where frail elderly patients had seen their breathing and movement improve with an infusion of … Global Stem Cell Media Market 2017- Lonza, Merck Millipore, Miltenyi Biotec and GE HealthcareJournalism Day |
Wall Street Journal |
Roche’s Immunotherapy Drug Tecentriq Extended Patients’ Lives in Study
Wall Street Journal Roche Holding AG RHHBY 1.26% said Thursday that its immunotherapy drug Tecentriq slowed the progression of lung cancer and helped patients live longer in a late-stage study, offering a new hope for patients and bolstering the Swiss drugmaker’s defense … |
|
Ovarian cancer could be next application for CAR T-cell therapy
ModernMedicine While CAR T-cell therapy has been proven to work for liquid—or blood—cancers, the challenge has been to apply this technology to solid tumors. That’s why Amit Kumar, PhD, president and CEO at ITUS Corporation, a San Jose, California-based cancer … |